OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine	258
Vaccination against Onchocerca volvulus induces IgG-mediated protective immunity dependent on neutrophils and complement	194
Mapping global public perspectives on mRNA vaccines and therapeutics	145
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	136
The dengue-specific immune response and antibody identification with machine learning	126
Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine	103
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year	98
A viral codon usage strategy enhances antigen production and protection in SFTSV mRNA vaccination	98
Rational development of a combined mRNA vaccine against COVID-19 and influenza	98
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection	82
Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 vaccine in cattle	79
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity	77
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	77
Tetravalent microprojection-based dengue chimeric virus vaccine raises potent neutralising antibodies in mice	76
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization	71
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle	70
Assessing immunogenicity barriers of the HIV-1 envelope trimer	69
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice	68
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines	67
Reverse development of vaccines against antimicrobial-resistant pathogens	65
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys	62
Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice	61
A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens	61
Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses	58
Author Correction: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax	57

Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen	57
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants	57
mRNA-LNP vaccine encoding CDV hemagglutinin confers effective protection in raccoon dogs	56
Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates	55
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex	54
Leishmania tarentolae as a platform for the production of vaccines against viral pathogens	54
Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters	50
PfRH5 vaccine; from the bench to the vial	49
LmCen−/− based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia	48
Genome-wide association study of myocarditis and pericarditis following COVID-19 vaccination	48
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth	47
A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark	46
IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell development	45
A field test of empathetic refutational and motivational interviewing to address vaccine hesitancy among patients	44
Antibody responses against influenza A decline with successive years of annual influenza vaccination	44
Single-dose intranasal adenovirus-based RSV vaccines targeting G and M2	43
An open repository of COVID-19 vaccine mandate studies with a worked scoping review of quasi-experimental evidence	42